Eli Lilly & Co. (LLY) reports Tirzepatide reduced sleep apnea severity by up to nearly two-thirds in adults with obstructive sleep apnea (OSA) and obesity

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. DFTX
6. GOOGL
7. APGE
8. HOOD
9. MU
10. IBM

Go back to Eli Lilly & Co. (LLY) reports Tirzepatide reduced sleep apnea severity by up to nearly two-thirds in adults with obstructive sleep apnea (OSA) and obesity

Eli Lilly (LLY) sleep apnea study data seen as a win, stock gains

April 17, 2024 11:12 AM EDT

Eli Lilly & Co. (NYSE: LLY) announced positive topline results from its SURMOUNT-OSA Ph3 study on Wednesday, which evaluated tirzepatide compared to placebo in patients with obesity and sleep apnea.

According to the company, the phase 3 clinical trials that showed tirzepatide injection significantly reduced the... More